Recombinant anti erbb2 her2 antibody

BT-474 cells were seeded in flat-bottom 6-well plates (1 × 10⁶ per well) and incubated overnight. The experiment was divided into three groups: (1) blank group; (2) trastuzumab group; (3) Tra-TTR-A group. After adding the corresponding solution to each group, all cells were incubated for another 4 h. In order to detect the expression of HER2, 1 × 10⁶ cells/100 μL were taken from each group to add into the primary antibody (recombinant anti-ErbB2/HER2 antibody, Abcam Company No: ab222482). The mixture was mixed well and then reacted at room temperature without light for 30 min. After that, the secondary antibody (FITC-labeled fluorescent antibody) was added and mixed evenly, and the reaction was carried out at room temperature for 30 min. Finally, 1 × PBS (500 μL) was used to resuspended each group into single cell suspension, and then, the expression of HER2 was detected by flow cytometry (BD ISRFortessa^TM).

The main reagents utilized in this contribution include 5-(4-(diphenylamino) phenyl) thiophene-2-carbaldehyde 1 (from 3A Chemical Co., Ltd.), 3-allylrhodanine 2, trastuzumab, recombinant anti-ErbB2/HER2 antibody (from Abcam Company No: ab222482), and DCFH-DA reactive oxygen species assay kit (from Aladdin Co., Ltd.), all of which were of analytical grade. The main instruments utilized in this contribution include the Zetasizer Nano ZSP (Malvern Instruments, UK.), UV (ultraviolet-visible) spectrophotometer (Thermo Fisher evolution 300), spectrofluorometer (Thermo Scientific lumina), ELISA microplate reader (BioTek elx80), flow cytometry (BD ISRFortessa^TM), and small animals' living imaging system (Bruker FX pro).